Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2009-10-30 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing the approval of a biological drug (Ilaris) in the EU for treating CAPS. It contains detailed information about the drug, clinical trial data, regulatory status, and forward-looking statements. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management report. It is a regulatory filing that provides material information to investors but does not fit into other specific categories like earnings release or capital update. The length is substantial (over 14,000 characters), and it is a formal SEC filing (Form 6-K) which is commonly classified as Regulatory Filings (RNS) when it contains press releases or similar disclosures. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-10-30 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release about the progress and production of the Influenza A (H1N1) vaccine, including shipment volumes, production capacity, and forward-looking statements. It is not a full annual or quarterly report, audit report, or earnings release. It is a regulatory announcement providing operational updates and forward-looking information. The document length is over 10,000 characters and contains detailed information but does not include comprehensive financial statements or detailed financial analysis. It is a typical Form 6-K report used by foreign private issuers to provide material information to the SEC and investors. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2009-10-30 English
SECURITIES TO BE OFFERED UNDER EMPLOYEE BENEFIT PLANS
Regulatory Filings Classification · 100% confidence The document is a Form S-8 registration statement filed with the SEC by Novartis AG. Form S-8 is used for registering securities to be offered under employee benefit plans. The text includes details about the securities to be registered, incorporation by reference of other filings, indemnification of directors and officers, and signatures. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial and contains detailed legal and regulatory information, not a brief announcement or a report publication announcement.
2009-10-29 English
Regulatory Filings 2009
Regulatory Filings Classification · 100% confidence The document is a Form F-6 Registration Statement filed with the SEC for the registration of American Depositary Shares evidenced by American Depositary Receipts (ADRs) for Novartis AG. It includes details about the securities to be registered, the deposit agreement, legal opinions, certifications, and signatures of company officers and directors. The document is a regulatory filing related to securities registration under the Securities Act of 1933, specifically for ADRs, and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report but a registration statement for securities issuance. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-10-29 English
6-K
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by Novartis AG, reporting financial results for the first nine months of 2009. It includes detailed financial data such as net sales, operating income, net income, earnings per share, and segment performance. The document is titled as a financial report and quarterly report ("RAPPORT TRIMESTRIEL" and "QUARTALSBERICHT"), indicating it is an interim or quarterly report. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. It is not an announcement or a brief summary but a comprehensive report with actual financial statements and commentary. Therefore, the correct classification is Interim / Quarterly Report (IR).
2009-10-27 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the approval of a new pharmaceutical product (Exforge HCT) in the European Union. It includes detailed information about the product, clinical study results, and forward-looking statements. There are no financial statements or comprehensive financial performance data presented. The document is not an annual or interim report, audit report, earnings release, or any other financial report type. Instead, it is a regulatory filing providing material information to investors and the SEC about a significant corporate event (product approval). Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2009-10-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.